Repligen awards chief product officer 675 options

Q: What stock awards did Repligen's chief product officer receive?

Chief Product Officer Brian Robb Douglass was awarded 700 restricted stock units and options to buy 675 common shares on October 6, 2026. The options have a $174.86 per-share exercise price.

The awards have separate vesting schedules: the RSUs vest over three years, while the option shares vest annually through October 6, 2029.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Repligen Corp. (RGEN) Chief Product Officer Brian Robb Douglass was awarded 700 restricted stock units and options to buy 675 common shares on October 6, 2026. The RSUs vest in equal annual installments over three years beginning on the first anniversary of the grant. The options have a $174.86 per-share exercise price; 225 shares vest on October 6, 2027, October 6, 2028, and October 6, 2029, and the options expire October 6, 2036. His directly held common stock following the RSU award was 8,685 shares.

Insider Trade Summary

Grant/Award: 1,375 shares

Grant/Award 2 txns

Insider Douglass Brian Robb

Role CHIEF PRODUCT OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F2	675	$0.00	$0.00
Grant/Award	Common Stock ^F1	700	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 675 contracts (Direct); Common Stock — 8,685 shares (Direct)

Footnotes (2)

F1. Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2. 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029.

Key Figures

Restricted stock units awarded: 700 units Options to buy common shares awarded: 675 shares Exercise price: $174.86 per share +3 more

6 metrics

Restricted stock units awarded 700 units Awarded October 6, 2026

Options to buy common shares awarded 675 shares Awarded October 6, 2026

Exercise price $174.86 per share Stock option award

Shares vesting per option installment 225 shares October 6, 2027, October 6, 2028, and October 6, 2029

Directly held common stock following RSU award 8,685 shares Following the October 6, 2026 award

Option expiration date October 6, 2036 Stock option award

Key Terms

restricted stock units, contingent right, Stock Option (Right to Buy), vest in equal annual installments

4 terms

restricted stock units financial

"awarded 700 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest in equal annual installments financial

"vest in equal annual installments over a three-year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock awards did Repligen's chief product officer receive?

Chief Product Officer Brian Robb Douglass was awarded 700 restricted stock units and options to buy 675 common shares on October 6, 2026. The options have a $174.86 per-share exercise price.

How are Repligen's restricted stock units settled?

Each restricted stock unit represents a contingent right to receive one Repligen common share. The units may be settled only by delivering shares of Repligen common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/08/2026 - 04:40 PM EDT Accepted by SEC EDGAR 10/08/2026 - 04:40 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Douglass Brian Robb

(Last)

(First)

(Middle)

C/O REPLIGEN CORPORATION

41 SEYON ST., BLDG 1, STE 100

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF PRODUCT OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/06/2026		A		700⁽¹⁾	A	$0	8,685	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$174.86	10/06/2026		A		675		⁽²⁾	10/06/2036	Common Stock	675	$0	675	D

Explanation of Responses:

1. Mr. Douglass was awarded 700 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. 225 shares will vest on each of October 6, 2027, October 6, 2028, and October 6, 2029.

Remarks:

	/s/ Meghan Stapleton (Attorney in Fact)	10/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR